Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial.

Thomas SeufferleinLudwig LausserAlexander SteinDirk ArnoldGerald PragerStefan KasperMichael NiedermeierLothar MüllerStefan KubickaAlexander KönigPetra Büchner-SteudelKai WilleAndreas W BergerAngelika M R KestlerJohann M KrausSilke D WerleLukas PerkhoferThomas J EttrichHans Armin Kestler

Published in: PloS one (2024)

We identified a CAF marker combination that indicates treatment resistance to FOLFOX plus bevacizumab in patients with mCRC within 100 days prior to radiologic progress.

Keyphrases

metastatic colorectal cancer
clinical trial
study protocol
phase iii
cross sectional
phase ii
randomized controlled trial
combination therapy
open label